AbbVie Science

Oncology Pipeline

Investigational drugs mentioned are for use in clinical studies only, and may be studied alone or in combination with drugs for indications that have not been approved by the FDA. Approved drugs mentioned are also being studied for uses for which they are not approved. Safety and efficacy have not been established for any of these drugs for the uses being studied. AbbVie in no way intends to recommend or imply that these drugs should be used for unapproved uses.

Heading Hematological

Heading Solid Tumors

Tumor Intrinsic Small

BCL-2 Inhibitor

BCL-2 Inhibitor

FRα DM21Biparatopic ADC

Immuno-Oncology Small

CLBR001 + SWI019

CD3 x CD20 BsAb

CD3 X BCMA BsAb

For a complete list of oncology pipeline molecules see abbvie.com
*ImmunoGen is now part of AbbVie.
Venetoclax jointly developed with Roche. Ibrutinib jointly developed with Janssen Biotech. Epcoritamab developed in partnership with Genmab. CLBR001 / SWI019 developed by Calibr is in a first-in-patient trial and AbbVie hold options for additional development and other targets. TTX-030 developed by Trishula Therapeutics through Phase 1b and AbbVie has option to lead global development. ABBV-CLS-579 / 484 is being co-developed by Calico and AbbVie. Calico is responsible for advancing into Phase 2a with AbbVie’s support. AbbVie has the option to manage late-stage development and commercial activities.
Livmoniplimab was developed in partnership with Argenx. † Dragonfly Therapeutics TriNKET® technology.

ADC=Antibody-Drug Conjugate.
mAb=Monoclonal Antibody.
sCAR T=Switchable Chimeric Antigen Receptor T-Cell.